STIM - Neuronetics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.2900
-0.1800 (-4.03%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.4700
Open4.5000
Bid0.1000 x 800
Ask4.5000 x 900
Day's Range4.1200 - 4.5100
52 Week Range3.9600 - 20.3600
Volume291,383
Avg. Volume133,787
Market Cap80M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.5220
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.75
  • GlobeNewswire

    Neuronetics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    MALVERN, Pa., Nov. 25, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire

    Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

    Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc.  As a result of the transaction, Microchips is a wholly owned subsidiary of Daré. Microchips is developing an innovative, wireless, user-controlled drug delivery technology with potential utility across multiple therapeutic areas, including contraception. The application of this technology in developing a contraceptive product has been supported by the Gates Foundation in the form of approximately $17.9 million in grant funding to date.

  • PR Newswire

    Neuronetics® to Present New Depression Research at 15th Annual Neuroscience Education Institute Congress

    Data confirms NeuroStar® Advanced Therapy is a proven and safe treatment option for those with medication-resistant depression MALVERN, Pa. , Nov. 7, 2019 /PRNewswire/ -- Neuronetics, Inc. (NASDAQ: STIM), ...

  • Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
    Zacks

    Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates

    Neuronetics (STIM) delivered earnings and revenue surprises of 9.76% and -0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Neuronetics Reports Third Quarter 2019 Financial and Operating Results

    MALVERN, Pa., Nov. 05, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire

    Neuronetics® Announces Appointment of Sheryl Conley to its Board of Directors

    Neuronetics, Inc. (STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Sheryl Conley to its Board of Directors, effective immediately. Ms. Conley will be a member of the Audit Committee and after her appointment, the Neuronetics’ Board of Directors will have seven members. "We are thrilled to welcome Sheryl to the Board of Neuronetics as we look to advance our mission of improving the quality of life for patients who suffer from psychiatric disorders," said Chris Thatcher, President and CEO of Neuronetics.

  • How Much Are Neuronetics, Inc. (NASDAQ:STIM) Insiders Taking Off The Table?
    Simply Wall St.

    How Much Are Neuronetics, Inc. (NASDAQ:STIM) Insiders Taking Off The Table?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Neuronetics (STIM) to Report a Decline in Earnings: What to Look Out for

    Neuronetics (STIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire

    Neuronetics® and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar® Advanced Therapy

    MALVERN, Pa., Oct. 28, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced a partnership with Success TMS, a healthcare provider specializing in transcranial magnetic stimulation (TMS), a non-drug, non-invasive treatment for adult patients with Major Depressive Disorder (MDD). As part of a three-year agreement, Success TMS will offer Neuronetics' NeuroStar Advanced Therapy system as its preferred TMS device at 21 locations across six states.

  • GlobeNewswire

    Neuronetics to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Oct. 22, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • PR Newswire

    Neuronetics CEO Chris Thatcher to Ring Nasdaq Closing Bell on October 22 in Honor of National Depression Awareness Month

    MALVERN, Pa., Oct. 21, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will ring the Nasdaq Closing Bell on October 22 in honor of National Depression Awareness Month.

  • PR Newswire

    Neuronetics® Unveils Promising New Depression Research Data at Psych Congress

    New findings confirm safety and efficacy of NeuroStar® Advanced Therapy, a non-drug depression treatment, setting the stage for future indications MALVERN, Pa. , Oct. 3, 2019 /PRNewswire/ -- Neuronetics, ...

  • PR Newswire

    Neuronetics® Honors Depression Conquerors For National Depression Awareness Month

    MALVERN, Pa., Oct. 1, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, is spotlighting the many faces and stories of depression to encourage an open dialogue and awareness of its non-drug treatment option in honor of National Depression Awareness Month. Sharing the stories of patient advocates who have been positively impacted by NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment, Neuronetics aims to educate on an innovative, safe and effective treatment option patients can turn to when antidepressant medications fail.

  • PR Newswire

    Neuronetics® Announces Greenbrook® TMS Installation Milestone for NeuroStar® Advanced Therapy System

    MALVERN, Pa., Sept. 4, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Greenbrook TMS, a NeuroStar Advanced Therapy provider with 82 treatment centers across the U.S., has installed its 100th NeuroStar system. This is a significant milestone in the availability of NeuroStar Advanced Therapy transcranial magnetic stimulation (TMS) treatment for patients. Greenbrook's Matthews, NC location now joins the growing number of practices offering NeuroStar TMS.

  • Is Neuronetics (NASDAQ:STIM) Using Debt In A Risky Way?
    Simply Wall St.

    Is Neuronetics (NASDAQ:STIM) Using Debt In A Risky Way?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • PR Newswire

    Researchers at USU Unveil Neuronetics®-supported Clinical Research for PTSD and Traumatic Brain Injury at the Military Health System Research Symposium

    MALVERN, Pa., Aug. 19, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced that researchers at the Uniformed Services University of the Health Sciences will present clinical data at the 2019 Military Health System Research Symposium (MHSRS) in Kissimmee, FL from August 19-22 from an investigator-initiated trial utilizing the Company's NeuroStar® Advanced Therapy TMS research system for PTSD and traumatic brain injury (TBI). In addition, they will present a case report of one patient treated and studied for Alzheimer's Disease.

  • Neuronetics, Inc. (STIM) Q2 2019 Earnings Call Transcript
    Motley Fool

    Neuronetics, Inc. (STIM) Q2 2019 Earnings Call Transcript

    STIM earnings call for the period ending June 30, 2019.

  • Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

    Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 4.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Neuronetics Reports Second Quarter 2019 Financial and Operating Results

    MALVERN, Pa., Aug. 06, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • PR Newswire

    Neuronetics® Announces First TMS Patient Treated Under New Japan Reimbursement Policy

    MALVERN, Pa., Aug. 1, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced that Kanagawa Psychiatric Center is treating the first patient in Japan using NeuroStar® Advanced Therapy under the newly approved reimbursement listing by Japan's Ministry of Health, Labour and Welfare (MHLW) and the Central Social Insurance Medical Council (Chuikyo).

  • PR Newswire

    Neuronetics® Launches TrakStar® Plus Patient Data Management System to Maximize Physician Time with Patients

    MALVERN, Pa., July 29, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), the developer of NeuroStar® Advanced Therapy, the market leader in transcranial magnetic stimulation (TMS) for depression, announced today the launch of its TrakStar® Plus patient data management system. Based on feedback from physicians on the front lines of care who are actively treating patients with Major Depressive Disorder (MDD) with the NeuroStar device, these new features are focused on improving workflow, usability and access.

  • GlobeNewswire

    Neuronetics to Present at the 39th Annual Canaccord Genuity Growth Conference

    MALVERN, Pa., July 25, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire

    Neuronetics to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release second quarter 2019 financial and operating results, and certain guidance for the third quarter and full year 2019, prior to market open on Tuesday, August 6, 2019. Chris Thatcher, Chief Executive Officer, and Stephen Furlong, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 a.m. Eastern Time the same day. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 6595410, approximately ten minutes prior to start time.

  • These 4 Medical Stocks Could Benefit From J&J Earnings — Here's Why
    Investor's Business Daily

    These 4 Medical Stocks Could Benefit From J&J Earnings — Here's Why

    JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology. Penumbra works in stroke treatment.

  • PR Newswire

    NeuroStar® Patient Outcomes Registry Has Now Surpassed 3,000 Evaluable Patients, Making It The World's Largest in Major Depressive Disorder

    MALVERN, Pa., July 8, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM) – Neuronetics, Inc., the developer of NeuroStar® Advanced Therapy, announced today that its depression outcomes registry has reached 3,223 evaluable patients, making it the largest outcomes registry in the world for Major Depressive Disorder (MDD). Launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment with NeuroStar Advanced Therapy in real-word clinical settings, the registry has surpassed the number of evaluable patients in the STAR*D study (n=2,876), making it the largest registry focused on therapies for the treatment of depression.